Evidence-based guidelines recommend inhaled long-acting anti-muscarinic agents
(LAMAs) as first-line maintenance therapy for symptomatic patients with COPD. Several …

Chronic obstructive pulmonary disease (COPD) pharmacological treatment aims to reduce
symptoms, represented mostly by dyspnoea and its impact on daily life, and future risk, ie …

Long-acting inhaled bronchodilator medications are recommended as initial maintenance
therapy for many patients with COPD. These medications include long-acting muscarinic …

The purpose of this study was to systematically review the efficacy and safety of long-acting
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …

A large, randomized, double-blind, multicenter, noninferiority trial revealed consistent
superiority in exacerbation reduction, functional respiratory improvement, and quality-of-life …

Purpose To assess the comparative efficacy of short-acting muscarinic antagonists (SAMAs),
long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta …

Objective: To compare the available literature regarding the use of long-acting muscarinic
antagonist (LAMA)/long-acting β2 agonists (LABA) and inhaled corticosteroid (ICS)/LABA …

Several long‐acting bronchodilators have been developed and are widely used as first‐line
treatment in patients with stable chronic obstructive pulmonary disease (COPD). However …

Some trials have been conducted to compare long‐acting muscarinic antagonist (LAMA)+
long‐acting beta agonist (LABA) versus LABA+ inhaled corticosteroids (ICS) for chronic …

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide,
whose burden is expected to increase in the next decades, because of numerous risk …